Nurix's Losses Widen to $186M Amid Soaring R&D Costs

TL;DR

**Nurix is burning cash at an alarming rate to fund its early-stage pipeline, making it a high-risk bet unless they secure significant new funding or hit a major clinical milestone soon.**

AI Summary

Nurix Therapeutics, Inc. reported a significant increase in net loss for the nine months ended August 31, 2025, reaching $(186.2) million, up from $(135.0) million in the prior year, primarily driven by a substantial rise in research and development (R&D) expenses. R&D expenses surged to $233.9 million for the nine-month period in 2025, compared to $154.4 million in 2024, reflecting increased clinical trial activities for lead drug candidates like bexobrutideg (NX-5948), zelebrudomide (NX-2127), and NX-1607. Total revenue for the nine months ended August 31, 2025, increased to $70.4 million, up from $41.3 million in 2024, largely due to a $30.0 million license revenue recognized in 2025, offsetting a slight decrease in collaboration revenue from $41.3 million to $40.4 million. The company's cash and cash equivalents, along with marketable securities, decreased from $609.6 million as of November 30, 2024, to $428.8 million as of August 31, 2025, indicating a significant cash burn. Nurix continues to operate at a substantial loss and will require additional funding to support its ongoing clinical development programs, as highlighted by its net cash used in operating activities of $(181.6) million for the nine months ended August 31, 2025.

Why It Matters

Nurix's escalating R&D expenses and widening net loss signal a critical juncture for investors, as the company burns through cash to advance its early-stage clinical pipeline. The $30 million license revenue provides a temporary boost but doesn't offset the fundamental need for substantial additional funding, posing a significant risk to future operations and stock value. For employees, continued losses could raise concerns about job security and long-term stability, while customers (future patients) depend on the successful, albeit costly, progression of drug candidates. In the competitive biopharmaceutical landscape, Nurix's ability to secure further financing and achieve clinical milestones will dictate its survival and potential to challenge established players in cancer and inflammatory disease treatments.

Risk Assessment

Risk Level: high — Nurix has incurred significant losses since inception, with a net loss of $(186.2) million for the nine months ended August 31, 2025, and expects to incur losses for at least the next several years. The company's cash and marketable securities decreased by $180.8 million from November 30, 2024, to August 31, 2025, indicating a rapid cash burn and a stated need for 'substantial additional funding' to continue operations.

Analyst Insight

Investors should exercise extreme caution and consider the high-risk nature of NRIX. Monitor closely for announcements regarding new financing rounds or significant clinical trial data for bexobrutideg (NX-5948), zelebrudomide (NX-2127), and NX-1607, as these will be critical catalysts for future valuation. Without clear progress or new capital, the current cash burn rate suggests significant dilution or operational curtailment.

Financial Highlights

debt To Equity

0.40

revenue

$70,403,000

operating Margin

-287.8%

total Assets

$522,472,000

total Debt

$150,220,000

net Income

$(186,236,000)

eps

$(2.22)

gross Margin

N/A

cash Position

$428,829,000

revenue Growth

+70.7%

Revenue Breakdown

Key Numbers

• $(186.2)M — Net Loss (Increased from $(135.0)M in 2024 for the nine months ended August 31, 2025)
• $233.9M — Research and Development Expenses (Increased from $154.4M in 2024 for the nine months ended August 31, 2025)
• $70.4M — Total Revenue (Increased from $41.3M in 2024 for the nine months ended August 31, 2025, driven by license revenue)
• $30.0M — License Revenue (Recognized for the nine months ended August 31, 2025, contributing to revenue growth)
• $(181.6)M — Net Cash Used in Operating Activities (For the nine months ended August 31, 2025, indicating significant cash burn)
• $428.8M — Cash, Cash Equivalents and Marketable Securities (Decreased from $609.6M as of November 30, 2024, to August 31, 2025)
• 76,883,436 — Shares of Common Stock Outstanding (As of September 30, 2025)
• $(1.03) — Net Loss Per Share (3 months) (Increased from $(0.67) in the prior year quarter)
• $(2.22) — Net Loss Per Share (9 months) (Increased from $(2.13) in the prior year period)
• $372.3M — Total Stockholders' Equity (Decreased from $527.0M as of November 30, 2024)

Key Players & Entities

• Nurix Therapeutics, Inc. (company) — Registrant
• Gilead Sciences, Inc. (company) — collaboration partner
• Sanofi S.A. (company) — collaboration partner
• Seagen Inc. (company) — collaboration partner, now part of Pfizer Inc.
• Pfizer Inc. (company) — acquired Seagen Inc.
• bexobrutideg (NX-5948) (drug_candidate) — lead drug candidate in clinical development
• zelebrudomide (NX-2127) (drug_candidate) — lead drug candidate in clinical development
• NX-1607 (drug_candidate) — lead drug candidate in clinical development
• DEL-AI platform (technology) — proprietary AI-integrated discovery platform
• Nasdaq Global Market (market) — exchange where NRIX common stock is registered

FAQ

Risk Factors

• Substantial Cash Burn and Need for Future Funding [high — financial]: The company experienced a net loss of $(186.2) million for the nine months ended August 31, 2025, and net cash used in operating activities was $(181.6) million. Cash, cash equivalents, and marketable securities decreased from $609.6 million to $428.8 million during the period. This significant burn rate indicates a continued need for additional funding to support ongoing clinical development programs.
• High R&D Expenses for Clinical Trials [high — operational]: Research and development expenses increased substantially to $233.9 million for the nine months ended August 31, 2025, from $154.4 million in the prior year. This increase is attributed to expanded clinical trial activities for lead drug candidates, which represents a significant investment and operational focus.
• Dependence on Drug Development Success [high — regulatory]: The company's future success is heavily dependent on the successful development and commercialization of its drug candidates, including bexobrutinib (NX-5948), zelebrudomide (NX-2127), and NX-1607. Any delays, failures in clinical trials, or regulatory hurdles could materially impact the company's financial condition and prospects.
• Decreasing Stockholders' Equity [medium — financial]: Total stockholders' equity decreased from $527.0 million as of November 30, 2024, to $372.3 million as of August 31, 2025. This decline is primarily due to the accumulated net losses, reflecting the company's current stage of development and ongoing investment.
• Reliance on Collaboration and License Agreements [medium — operational]: While license revenue provided a significant boost in the current period ($30.0 million), the company's revenue is also derived from collaboration agreements. Changes in these partnerships or the terms of such agreements could impact revenue streams.

Industry Context

The biopharmaceutical industry, particularly in the oncology and immunology space where Nurix operates, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Nurix rely heavily on innovation and the successful progression of drug candidates through clinical trials. The competitive landscape is intense, with many players vying for market share and significant investment from venture capital and public markets.

Regulatory Implications

Nurix's drug development pipeline is subject to stringent regulatory oversight by bodies like the FDA. Delays in clinical trials, failure to meet efficacy or safety endpoints, or changes in regulatory requirements can significantly impact the company's ability to bring its products to market and generate revenue. Compliance with evolving regulations is critical for continued operation and investment.

What Investors Should Do

1. Monitor R&D spending and clinical trial progress
2. Assess future funding needs and strategies
3. Analyze revenue diversification and sustainability
4. Evaluate the impact of increasing net loss per share

Key Dates

• 2025-08-31: Nine months ended August 31, 2025 financial reporting period — Shows increased net loss, significant R&D spending, and a substantial decrease in cash reserves, highlighting the company's burn rate and funding needs.
• 2024-11-30: Balance sheet date for comparison — Provides the starting point for the decrease in cash and marketable securities and stockholders' equity observed by August 31, 2025.

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company has not yet achieved profitability, with a significant accumulated deficit of $(925,005,000) as of August 31, 2025.)

Collaboration revenue

Revenue generated from agreements with other companies where research, development, or commercialization activities are shared. (Represents a portion of Nurix's revenue, which slightly decreased to $40,403,000 for the nine months ended August 31, 2025.)

License revenue

Revenue earned from granting rights to intellectual property, such as drug candidates, to other entities. (A significant contributor to Nurix's revenue in the current period, with $30,000,000 recognized for the nine months ended August 31, 2025.)

Net cash used in operating activities

The amount of cash a company has spent on its core business operations over a period. (A key indicator of cash burn, showing $(181.6) million used for the nine months ended August 31, 2025, underscoring the need for funding.)

Marketable securities

Short-term, highly liquid investments that can be readily converted into cash. (Part of the company's liquid assets, which decreased significantly from $499,586,000 to $350,391,000 between November 30, 2024, and August 31, 2025.)

Year-Over-Year Comparison

Compared to the prior year period, Nurix Therapeutics has seen a significant increase in total revenue, primarily driven by $30.0 million in license revenue, pushing it to $70.4 million for the nine months ended August 31, 2025, a 70.7% increase from $41.3 million. However, this revenue growth is overshadowed by a substantial rise in R&D expenses, which grew by 51.5% to $233.9 million, leading to a wider net loss of $(186.2) million from $(135.0) million. Cash reserves have also diminished considerably, with cash, cash equivalents, and marketable securities falling from $609.6 million to $428.8 million, indicating an accelerated cash burn.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share NRIX Nasdaq Global Market I

Filing Documents

• nrix-20250831.htm (10-Q) — 1531KB
• nrix-20250831x10qxex311.htm (EX-31.1) — 10KB
• nrix-20250831x10qxex312.htm (EX-31.2) — 10KB
• nrix-20250831x10qxex321.htm (EX-32.1) — 8KB
• 0001549595-25-000113.txt ( ) — 6401KB
• nrix-20250831.xsd (EX-101.SCH) — 42KB
• nrix-20250831_cal.xml (EX-101.CAL) — 53KB
• nrix-20250831_def.xml (EX-101.DEF) — 213KB
• nrix-20250831_lab.xml (EX-101.LAB) — 569KB
• nrix-20250831_pre.xml (EX-101.PRE) — 386KB
• nrix-20250831_htm.xml (XML) — 713KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Balance Sheets 1 Condensed Statements of Operations 2 Condensed Statements of Comprehensive Loss 3 Condensed Statements of Stockholders' Equity 4 Condensed Statements of Cash Flows 6 Notes to Condensed Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 38 Item 4.

Controls and Procedures

Controls and Procedures 38 PART II. OTHER INFORMATION 39 Item 1.

Legal Proceedings

Legal Proceedings 39 Item 1A.

Risk Factors

Risk Factors 39 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 98 Item 3. Defaults Upon Senior Securities 98 Item 4. Mine Safety Disclosures 98 Item 5. Other Information 98 Item 6. Exhibits 99

SIGNATURES

SIGNATURES 100 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements NURIX THERAPEUTICS, INC. CONDENSED BALANCE SHEETS (in thousands, except share and per share amounts) (unaudited) August 31, 2025 November 30, 2024 Assets Current assets: Cash and cash equivalents $ 78,438 $ 109,997 Marketable securities 350,391 499,586 Prepaid expenses and other current assets 11,774 9,804 Total current assets 440,603 619,387 Operating lease right-of-use assets 53,028 28,139 Property and equipment, net 20,498 17,757 Restricted cash 968 901 Other assets 7,375 3,159 Total assets $ 522,472 $ 669,343 Liabilities and stockholders equity Current liabilities: Accounts payable $ 8,609 $ 11,482 Accrued expenses and other current liabilities 43,957 37,994 Operating lease liabilities, current 3,791 8,014 Deferred revenue, current 25,993 38,364 Total current liabilities 82,350 95,854 Operating lease liabilities, net of current portion 52,695 20,289 Deferred revenue, net of current portion 15,175 26,207 Total liabilities 150,220 142,350 Commitments and contingencies (Note 6) Stockholders equity: Preferred stock, $ 0.001 par value— 10,000,000 shares authorized as of August 31, 2025 and November 30, 2024; no shares issued and outstanding as of August 31, 2025 and November 30, 2024 — — Common stock, $ 0.001 par value— 500,000,000 shares authorized as of August 31, 2025 and November 30, 2024; 76,872,686 and 75,870,718 shares issued and outstanding as of August 31, 2025 and November 30, 2024, respectively 77 76 Additional paid-in capital 1,297,061 1,265,536 Accumulated other comprehensive income 119 150 Accumulated deficit ( 925,005 ) ( 738,769 ) Total stockholders equity 372,252 526,993 Total liabilities and stockholders equity $ 522,472 $ 669,343 The accompanying notes are an integral part of these unaudited condensed financial statements. 1 Table of Contents NURIX THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPERATIONS (in thousands, except share and per share amounts) (unaudited) Thre

View Full Filing

View this 10-Q filing on SEC EDGAR